ArticleDiabetology & metabolic syndrome2025
Association of wearable device-measured physical activity with full-course diabetic retinopathy and retinal traits: insights from the middle-aged and older adult cohort.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exerkines in diabetic retinopathy: from mechanisms to therapeutic prospects.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeTo assess accelerometer-measured physical activity (PA) in patients with all stages of diabetic retinopathy (DR) and investigate its association with specific retinal structural metrics.
methodsThis extensive cohort study included 13,600 participants with an average age of 56.39 years. These subjects were divided into four groups: non-diabetes mellitus, prediabetes mellitus (Pre-DM), diabetes mellitus (DM) without DR, and DR. We evaluated multivariate-adjusted associations of PA with DR progression using logistic regression and with retinal sublayer thickness using hierarchical linear model (HLM). The mediating role of body mass index (BMI) was tested to investigate the true association between PA and the full spectrum DR.
resultsAs DR progressed, the durations of moderate-intensity PA (MPA) and moderate-vigorous PA (MVPA) decreased significantly by 29% (odds ratio (OR) = 0.71, 95% CI = 0.57-0.90) to 78% (OR = 0.22, 95% CI = 0.14-0.35) and 21% (OR = 0.79, 95% CI = 0.71-0.89) to 55% (OR = 0.45, 95% CI = 0.30-0.67), respectively. Morning MPA and MVPA (6:00-12:00) were protective factors against DR, whereas late-night PA (0:00-5:59) heightened DR risk. The multivariate-adjusted linear interaction model revealed that the positive effect of MPA and MVPA on the thickness of ganglion cell-inner plexiform layer (GCIPL), macular thickness (MT), and inner nuclear layer-external limiting membrane was significantly associated with DR disease status (interaction P < 0.05). Higher MPA and MVPA were correlated with accelerated thickening rates of the GCIPL and MT sublayers, ranging from Pre-DM to those with established DR. 35.7% and 58.7% of the associations between MPA, MVPA, and the full spectrum DR were mediated by lower BMI, respectively.
conclusionsThe diminution of PA is associated with the progression of DR and the attenuation of retinal sublayer thickness, and our findings support current PA recommendations promoting interventions to decelerate DR progression and preserve retinal health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.